Compare Adaptive Biotechnologies Corp (ADPT) vs Nutanix Inc (NTNX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Nutanix Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Nutanix Inc trades at $53.75 (market cap $14.53B). The key difference: Nutanix Inc is far larger — about 4.4× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Nutanix Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | NTNX | |
|---|---|---|
Market Cap | $3.33B | $14.53B |
Sector | Health | Technology |
52-Week High | $22.37 | $81.12 |
52-Week Low | $10.24 | $34.41 |
Enterprise Value | $3.19B | $14.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Nutanix (NTNX) trades at $52.42, up 2.22% with strong technical momentum and bullish analyst sentiment. The company demonstrates robust fundamentals with Q3 2026 earnings beating expectations, 87% gross margins, and projected revenue growth to $2.7B in 2026. Recent NVIDIA certification for Unified Storage and expanding enterprise partnerships highlight strategic positioning in hybrid cloud infrastructure.
Outlook remains positive with 62.5% analyst buy ratings and $56.55 consensus target, though elevated P/E ratio of 55.17 and RSI near overbought levels suggest near-term consolidation risk. Key catalysts include AI infrastructure adoption and VMware migration opportunities, while execution risks and competitive pressures require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →
